Profile data is unavailable for this security.
About the company
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-11.89m
- Incorporated2005
- Employees6.00
- LocationProMIS Neurosciences IncSuite 200, 1920 Yonge StreetTORONTO M4S 3E2CanadaCAN
- Phone+1 (416) 847-6898
- Websitehttps://www.promisneurosciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bolt Biotherapeutics Inc | 11.32m | -63.03m | 28.12m | 100.00 | -- | 0.270 | -- | 2.48 | -1.66 | -1.66 | 0.2987 | 2.73 | 0.0649 | -- | -- | 113,240.00 | -36.11 | -48.32 | -39.88 | -54.03 | -- | -- | -556.59 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 28.40m | 34.00 | -- | 17.99 | -- | 4.81 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Lisata Therapeutics Inc | 0.00 | -20.05m | 28.49m | 25.00 | -- | 0.6627 | -- | -- | -2.46 | -2.46 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -35.01 | -45.97 | -38.40 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -30.28m | 30.28m | 32.00 | -- | 0.4082 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 30.53m | 6.00 | -- | 395.95 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.57m | 30.79m | 0.00 | -- | -- | -- | -- | -0.0929 | -0.0929 | 0.00 | -0.0055 | 0.00 | -- | -- | -- | -624.25 | -- | -- | -- | -- | -- | -- | -- | -- | -173.44 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 31.84m | 4.00 | -- | 5.28 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 31.86m | 73.00 | -- | 1.15 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 31.90m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| IGC Pharma Inc | 1.35m | -13.00m | 32.22m | 67.00 | -- | 3.88 | -- | 23.96 | -0.2168 | -0.2168 | 0.0229 | 0.1098 | 0.0993 | 0.292 | 18.42 | 20,074.63 | -96.01 | -42.46 | -113.83 | -46.07 | 54.50 | 20.95 | -966.54 | -730.00 | 0.9252 | -- | 0.0188 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| NKGen Biotech Inc | -100.00bn | -100.00bn | 32.60m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.96m | 163.00 | -- | 0.1615 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Aligos Therapeutics Inc | 13.79m | -99.59m | 33.00m | 67.00 | -- | 0.5565 | -- | 2.39 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sphera Funds Management Ltd.as of 31 Mar 2024 | 1.83m | 9.67% |
| Affinity Asset Advisors LLCas of 31 Mar 2024 | 265.96k | 1.40% |
| Northeast Financial Consultants, Inc.as of 31 Mar 2024 | 100.00k | 0.53% |
| BMO Asset Management Corp.as of 31 Mar 2024 | 30.37k | 0.16% |
| Hara Capital LLCas of 31 Mar 2024 | 29.42k | 0.16% |
| IEQ Capital LLCas of 31 Mar 2024 | 26.04k | 0.14% |
| Fiduciary Trust Co.as of 31 Mar 2024 | 20.01k | 0.11% |
| Claret Asset Management Corp.as of 31 Mar 2024 | 10.83k | 0.06% |
| Geode Capital Management LLCas of 30 Apr 2024 | 8.62k | 0.05% |
| West Financial Services, Inc.as of 31 Mar 2024 | 3.30k | 0.02% |
